Recurrent homozygous CBL-inactivating mutations in myeloid malignancies decrease ubiquitin ligase activity that inactivates SRC family kinases (SFK) and receptor tyrosine kinases (RTK). However, the most important SFK and RTK affected by these mutations, and hence, the most important therapeutic targets, have not been clearly characterized. We compared SFK and RTK pathway activity and inhibitors in acute myeloid leukemia cell lines containing homozygous R420Q mutation (GDM-1), heterozygous deletion (MOLM13) and wild-type (WT) CBL (THP1, U937). As expected with CBL loss, GDM-1 displayed high KIT expression and granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity. Ectopic expression of WT CBL decreased GDM-1 proliferation but not cell lines with WT CBL. GDM-1, but not the other cell lines, was highly sensitive to growth inhibition by dasatinib (dual SFK and RTK inhibitor, LD50 50 nM); there was less or no selective inhibition of GDM-1 growth by sunitinib (RTK inhibitor), imatinib (ABL, KIT inhibitor), or PP2 (SFK inhibitor). Phosphoprotein analysis identified phosphorylation targets uniquely inhibited by dasatinib treatment of GDM-1, including a number of proteins in the KIT and GM-CSF receptor pathways (for example, KIT Tyr721, STAT3 Tyr705). In conclusion, the promiscuous effects of CBL loss on SFK and RTK signaling appear to be best targeted by dual SFK and RTK inhibition.
INTRODUCTION
Acquired somatic copy-neutral loss of heterozygosity (LOH), also referred as to uniparental disomy (UPD), is frequently found in myelodysplastic syndrome (MDS), MDS/myeloproliferative neoplasms (MDS/MPN) and secondary acute myeloid leukemia (AML) and may point towards genes harboring homozygous mutations.
1,2 UPD11q23.3 is present in 7% of patients with chronic myelomonocytic leukemia (CMML) and 11% of cases of AML derived from this condition. 3 --6 This recurrent lesion has been shown to coincide with homozygous CBL mutations, mostly located in ring finger (RFD) or linker domain of the gene. 4 --6 CBL is a member of the E3 ubiquitin ligase CBL family, which poly-or mono-ubiquitinates activated SRC family kinases (SFK) and various receptor tyrosine kinases (RTK). 7 --9 Inactivation of ubiquitination activity through mutations of the RFD may lead to enhanced and/or prolonged receptor signaling, which can contribute to the clinical phenotype of patients with CBL mutations. In contrast to patients with UPD11q, those who have LOH due to del11q only rarely had hemizygous CBL mutations and only 4/442 (0.9%) patients with heterozygous mutation of CBL were identified, suggestive of the tumor suppressor function of CBL. 6 CBL mutant cases are associated with monocytosis, monocytoid blasts and aberrant KIT expression. Serial studies showed acquisition of CBL mutations during malignant evolution. CBL mutations were shown to be an independent adverse factor for overall survival (hazard ratio 2.2 (95%CI; 1.2 --4)) (P ¼ 0.013). 6 Patients with CBL mutations were frequently treated with intense chemotherapy or stem cell transplantation, 6 suggesting that the aggressive biology of CBL mutant leukemia prompted the initiation of more aggressive therapies.
The poor prognosis associated with CBL mutations necessitates new treatment approaches. However, to date the impact of specific therapies currently available to patients with CBL mutant leukemia has not been explored. Identification of pathogenic pathways resulting from a blockade of the ubiquitination activity of CBL may provide clues as to possible molecular targets, including SFK and RTK. Our experiments were designed to clarify the pathogenesis of CBL mutations in myeloid malignancies, using 2 CBL mutant cell lines, in particular the GDM-1 cell line with a homozygous R420Q CBL mutation, as models for primary CBL mutant neoplasms with RFD mutations.
MATERIALS AND METHODS Patients
Informed consent was obtained according to protocols approved by the institutional boards of Cleveland Clinic, Johns Hopkins University and UCLA Medical Center. We enrolled 493 patients with various myeloid malignancies (179 MDS, 162 MDS/MPN, 55 MPN, 97 primary AML). Diagnosis was assigned according to WHO classification criteria. 10 
LOH detection in myeloid cell lines
In order to identify LOH without copy number loss, including UPD, uniparental trisomy (UPT) and uniparental tetrasomy, 30 cell lines with a myeloid phenotype (Supplementary Table 1 ) from the SNP Array Based LOH and Copy Number Analysis database from the Wellcome Trust Sanger Institute (http://www.sanger.ac.uk/) were checked. We identified the total copy number and minor allelic copy number in each cell line and identified UPD, UPT and uniparental tetrasomy when the minor allele was absent and the total copy number was two (UPD), three (UPT) or four (uniparental tetrasomy).
CBL sequencing and amplification refractory mutation system (ARMS)-PCR DNA was extracted either from fresh bone marrow, peripheral blood, or cell lines. To screen DNA for mutations in CBL (exons 8 --9), CBLB (exons 9 --10) and CBLC (exons 7 --8), direct genomic DNA or cDNA sequencing was performed as previously described. 6 For CBL R420Q mutation detection, RNA was extracted from cell lines by TRIzol (Invitrogen, Carlsbad, CA, USA) and allele-specific RT-PCR was performed. 100 ng of cDNA was amplified in 35-cycle PCR reaction at an annealing temperature of 58 1C. The status of the CBL R420Q mutations were determined by a DNA tetra-primer ARMS assay. The primer sequences were:
and 5 0 -ATCATCAGCTCGTTCATCATCATCATC-3 0 (G/G genotype: 323 bp and 216 bp bands; A/A: 323 bp and 163 bp bands). For sequencing purposes, cDNA samples were amplified using the outer primers.
Flow cytometry/immunohistochemistry
Bone marrow aspirates were stained using allophycocyanin-labeled murine anti-c-Kit (CD117, Beckman Coulter, Fullerton, CA, USA), fluorescein isothiocyanate-labeled murine anti-granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CD116, BD Biosciences, Franklin Lakes, NJ, USA), allophycocyanin-labeled murine anti-Flt3 (CD135, BD Biosciences), and anti-CD34 PE-Cy7 (Beckman Coulter). Using side scatter vs FL5 on a Beckman Coulter FC500, gates were set on CD34-positive cells and CD117 expression on the cell surface was evaluated. The cell surface expression of three RTKs (KIT, GMCSF receptor and FLT3) were also tested by flow cytometry.
RQ-PCR for CBL expression
For the measurement of CBL RNA expression, TaqMan PCR was performed (Applied Biosystems, Foster City, CA, USA). Primers and probes were purchased from Applied Biosystems gene expression assays products (CBL assay ID: Hs00231981_m1). The probe was labeled at its 5 0 termini with FAM. Minor groove binder was attached to the nonfluorescent quencher at the 3 0 terminal. Each reaction contained 10 ng of cDNA and TaqMan Universal PCR Master Mix. Real-time PCR and subsequent analysis were performed with the ABI Prism 7500 Fast Sequence Detection System using default conditions. Cell culture THP-1 was kindly provided by Professor S P Whitman. U937 and GDM-1 were purchased from ATCC (Manassas, VA, USA). NKM-1 cells were kindly provided by Dr Akihiro Abe. MOLM13 was purchased from DSMZ (Braunschweig, Germany). Cells were cultured in RPMI-1640 (Invitrogen) supplemented with 10% FBS at 37 1C and 5% CO 2 and when appropriate in the presence of human stem cell factor (SCF), recombinant human thrombopoietin (TPO), Flt3 ligand and macrophage colony-stimulating factor (M-CSF) (PeproTech, Rocky Hill, NJ, USA). The cells were also cultured in the presence of granulocyte colony-stimulating factor (G-CSF), GM-CSF and erythropoietin (Amgen, Thousand Oaks, CA, USA), dasatinib (BristolMyers Squibb, New York, NY, USA) and imatinib, sunitinib, the SRC family inhibitor PP-2, rapamycin, Ly294002 and U0126 (LC Laboratories, Woburn, MA, USA).
In certain circumstances hematopoietic colony cultures were performed. Bone marrow cells were plated in methylcellulose (Stem Cell Technologies, Vancouver, Canada) in the presence of 20 ng/ml GM-CSF and 2 U/ml erythropoietin. Total BM cells were plated at a density of 1 Â 10 5 cells/1 ml methylcellulose in 35-mm dishes. Colonies on duplicate plates were counted and the average number of CFU-GM was then calculated.
Lentiviral transduction
CBL cDNA (accession number NM_005188) was cloned into pLVX-dsREDMonomer-C1 expression vector (Clontech, Mountain View, CA, USA). Viral particles were prepared as follows: 293 cells were transfected with a mixture of pCMV-dR8.2/pCMV-VSVG/pLVX-dsRED-Monomer-C1 and Lipofectamine 2000 (Invitrogen). Cells were cultured for additional 48 h and medium with viral particles were harvested and concentrated. THP-1 and GDM-1 cell lines were infected with CBL shRNA (h) lentiviral particles (Santa Cruz Biotechnology, Paso Robles, CA, USA) in the presence of polybrene (Sigma-Aldrich, St Louis, MO, USA). The stable CBL-expressing and knocking down bulk cultures were selected using puromycin (1 ug/ml for GDM-1 and 4 ug/ml for THP-1).
Proliferation kinetics
Cell proliferation was measured using CellTiter AQueous Non-Radioactive Cell Proliferation Assay (Promega, San Leandro, CA, USA) or the cell viability analyzer Vi-CELL XR (Beckman Coulter). Briefly, 1000 cells were incubated in 100 ml RPMI/cell for 72 h. 100 ml of (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-zolium, inner salt; MTS) was added to each well, incubated for an additional 1 h at 37 1C and the absorbance at 490 nm recorded with a Victor plate reader (PerkinElmer, Waltham, MA, USA). Alternatively, cell lines were washed twice and resuspended in RPMI 1640 with FCS alone or supplemented with the indicated growth factors or with inhibitors at 2 Â 10 5 cells/ml. Viable cells were determined by trypan blue exclusion and were counted after 72 h culture.
Phospho-specific protein microarray analysis
For detection of 228 site-specific tyrosine phosphorylation profiles with six replicates each, 100 ug of cell lysate was labeled with biotin and hybridized on Tyrosine Phosphorylation ProArray (Full Moon BioSystems, Sunnyvale, CA, USA) using Antibody Array Assay Kit (Full Moon BioSystems). The conjugated labeled protein was detected using Cy3-streptavidin. Fluorescence intensity was scanned by GenPix 4000B (Molecular Devices, Sunnyvale, CA, USA) using GenePix Pro software (Molecular Devices). For the data analysis, background signals and negative control value were removed from all measurements. The results from the six replicate samples are averaged, including actin value. After divided by the averaged actin value in each experiment, the reduction rate of phosphorylation by the treatment of tyrosine kinase inhibitors was computed as follows: Reduction rate (%) ¼ (Averaged value with treatment --Averaged value without treatment) / Averaged value without treatment Â 100.
RESULTS

UPD11q and CBL mutations in myeloid cell lines
We selected 30 cell lines derived from non-lymphoid leukemias, including erythroid, megakaryocytic, monocytic leukemias from a collection of 127 hematopoietic and lymphoid cell lines in the Wellcome Trust Sanger Institute database (http://www.sanger. ac.uk/cgi-bin/genetics/CGP/cghviewer/CghViewer.cgi; Supplementary Table 1 ). Using single-nucleotide polymorphism (SNP) array data, we detected 150 regions of copy number neutral LOH (Supplementary Figure 1 ); all chromosomes were affected, with chromosome 9 most frequently affected (22/30; 73% p-arm; 33%, q-arm; 40%)). We identified three instances of LOH without copy number loss located on chromosome 11q (2 UPD and 1 UPT), including 11q13.1 --q23.3 (UPD) in ML-2, 11q13.4-qter (UPD) in NKM-1 and 11q12.3-qter (UPT) in GDM-1 (Figure 1a ), of which 2 (NKM-1 and GDM-1) spanned the CBL locus (ch11:118,582,200-118,684,069) ( Figure 1a ). When we sequenced CBL in these cell lines, we identified a R420Q missense mutation in GDM-1 (Figures 1b --d) . This recurrent mutation has been reported to affect ubiquitination activity and to be associated with cytokine-independent growth.
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ARMS-PCR was designed for the R420Q mutation; as expected, we detected only mutated allele, whereas the wild-type (WT) allele was absent (Figures 1b--d) .
Sequencing of the NKM-1 and ML-2 cell lines did not reveal the presence of CBL mutations. As reported previously, a CBL gene splice mutation (deletion of exon 8-intron 8 boundary) was found in MOLM-13.
12 By RT-PCR-based sequencing, CBL WT expression was observed as well as the mutant, with a shorter transcript.
When we tested 493 samples from primary myeloid malignancies, we found homozygous R420 mutations in 5 cases of monocytoid AML (29% of all CBL mutant cases), including three missense and two frame shift mutations (Supplementary Table 2 ). All mutant cases showed a strong surface expression of KIT, suggesting defective receptor disposal due to a lack of receptor ubiquitination. In agreement with the findings in primary cells, CBL mutant GDM-1 (derived from a patient with secondary AML of a monocytic phenotype) also showed high KIT expression (Supplementary Figure 2A , B).
Impact of overexpression of WT CBL on GDM-1 We used GDM-1 as a model to study agents with potential activity in CBL mutant leukemias. THP-1, a monocytic cell line without a CBL mutation, was used as a WT control. After transduction of WT CBL in GDM-1 and THP-1, ectopic expression of CBL cDNA was 20 times higher than control vector experiments in both cell lines (Figure 2a) . By ARMS-PCR we detected only the WT allele in THP-1, and both the WT and R420Q mutant alleles in GDM-1 (Figure 2b) . Overexpression of WT CBL suppressed the growth of CBL mutant GDM-1, whereas it had no effect on THP-1 (Figure 2c ). Although ShRNA knockdown suppressed expression of WT and R420Q mutant CBL to o60% in GDM-1 and THP-1, respectively ( Figures  2a and b) , no significant impact on growth of either the mutant or WT cell lines was found (Figure 2c ).
Interaction of growth factors and CBL homozygous mutations
To evaluate RTK hypersensitivity in homozygous CBL mutant cells, we studied the effect of growth factors on GDM-1. We cultured cells with and without 10 ng/ml of SCF, TPO, FLT3L, G-CSF, M-CSF and GM-CSF for 3 days (Supplementary Figure 2C) . GM-CSF was the most effective in augmenting proliferation of GDM-1 (2.7-fold) followed by TPO (1.6-fold) as compared with controls (Supplementary Figure 2C ). Consistent with this finding, we also detected high expression of the GM-CSF receptor on the surface of GDM-1 (Supplementary Figure 2D) . When induction of WT CBL in GDM-1 on the response to growth factors was examined, the hyperproliferative response to GM-CSF was decreased as compared with a control vector infection (Figure 2d) . A similar effect was observed in the presence of TPO (Figure 2e ).
Effect of dasatinib treatment on GDM-1
We have compared the differential effects of various RTK and SFK inhibitors, including sunitinib, dasatinib, imatinib and PP2, on the proliferation of GDM-1, 2 control cell lines (WT CBL) and heterozygous CBL mutant MOLM-13 cells. We also used several inhibitors operating downstream of RTK and SFK, including rapamycin, Ly294002 and U0126 for mTOR, PI3K and MAPK, respectively. The selectivity of inhibitory effects was calculated as a ratio between GDM-1/the other cell lines. GDM-1 showed increased sensitivity to the SFK inhibitors dasatinib (LD50 50 nM vs 41000 nM) as compared with the other cell lines (Figure 3a) . Sunitinib, rapamycin, LY294002 and U0126 demonstrated almost equal responses between GDM-1 and the other cell lines and blocked growth of all cell lines irrespective of the CBL function (Figure 3a) . No differential sensitivity was found in MOLM-13 cells heterozygous for CBL mutation.
TK inhibitors and tyrosine phosphorylation levels Using a phosphoarray, we analyzed the tyrosine phosphorylation profiles of GDM-1 with or without TKI inhibitors and assessed which kinases were inhibited in association with the suppressive Over expression and knockdown of CBL and growth factor sensitivity in GDM-1 with over expression of WT CBL. (a) CBL was overexpressed (expression vector) and knocked down (shRNA) in THP-1 and GDM-1 via lentiviral transduction. mRNA copy number of CBL and GAPDH was measured by real-time quantitative PCR in triplicate. Relative CBL expression was calculated as CBL copy number divided by GAPDH copy number. In each control experiment using an empty plasmid, the value of expression was defined as 1. The data represent mean ± s.e.m. (b) Allelic status of residue 420 of CBL was confirmed by allele-specific PCR. Amplification bands of 216bp and 163bp indicate WT and mutated allele, respectively. (c) Cell viability was evaluated by MTS assay in over expression and knockdown experiments in the cell lines with WT (THP-1) and mutated CBL (GDM-1). In each control experiment using an empty plasmid, the value of expression was defined as 1. The data represent means±s.e.m. *Indicates a statistically significant difference (Po0.05). GDM-1 was cultured with GM-CSF (d) or TPO (e) for 72 h and viable cells were counted by trypan blue exclusion with overexpression of CBL or with empty vector transduction as control. Assays were performed in triplicate and the data represent means ± s.e.m.
allowed us to discern phosphorylation targets uniquely associated with inhibitory effects of dasatinib in GDM-1 (Figure 3a) . We detected the phosphorylation of 26 proteins (29 tyrosine sites), which are reduced specifically by dasatinib treatment, including not only RTK (KIT, FGFR1 and M-CSFR) but also other phosphorylated proteins (SRC, STAT1, STAT3 and P73) (Figure 4c ). Some of these proteins are associated with the downstream cascades of activated KIT and GM-CSF receptor.
Growth suppression by dasatinib in a patient sample with a homozygous CBL RFD mutation To confirm the effects of dasatinib in primary cells, we also performed semisolid cultures of bone marrow derived from an AML patient with R420Q mutation with and without dasatinib (10 nM) and compared the effects to cultures of control bone marrow from three AML patients without CBL mutation. We observed a 95% reduction of colony counts in the patient sample.
In contrast, the reduction effect of colony counts was less pronounced (28 --71%) in the patients with WT CBL (Figure 3b ).
DISCUSSION
Based on the observation that most of the mutations in CBL found in patients were homozygous, we identified cell lines with UPD11q and sequenced CBL in a targeted fashion. As a result, we found a CBL RFD R420Q homozygous mutation with LOH with trisomy 11q and concurrent UPT in the GDM-1 cell line derived from a patient with secondary AML. Because R420 was one of the most commonly affected residues in patients, 3 --6,11 GDM-1 cells are an appropriate model of myeloid malignancies with homozygous CBL mutation, whereas MOLM-13 has retained a copy of WT CBL, which may be protective and the interactions with other specific mutations and a single mutated CBL allele may make this cell line unique and not representative. Conversely, one would expect that MOLM-13 would show similar behavior as GDM-1 transduced with 
PDGF-R beta (Phospho-Tyr740) KIT ( Figure 4 . Reduction effect of tyrosine kinase inhibitors on protein phosphorylation in GDM-1. Tyrosine phosphorylation in GDM-1 with treatment of dasatinib (a) or sunitinib (b) was comprehensively investigated using an antibody microarray system. The results from the six replicate samples were averaged, including actin value. After division by averaged actin value in each experiment, the reduced rate of phosphorylation by the treatment of tyrosine kinase inhibitors was computed as follows: Reduction rate (%) ¼ (Averaged value with treatment --Averaged value without treatment) / Averaged value without treatment Â 100. Dasatinib (10 nM) reduced the phosphorylation of 44/288 tyrosine sites. As an example, ICAM1 Tyr512, IGF1R Tyr1161 and STAT3 Tyr705 phosphorylation levels were diminished (a). Phosphorylation levels were decreased at 56 sites in sunitinib-treated GDM-1 (b). (c) Comparison of inhibitory spectrum of dasatinib and sunitinib resulted in the identification of phophorylation targets uniquely associated with inhibitory effects of dasatinib in GDM-1. Phosphorylation of 26 proteins (29 tyrosine sites) was reduced specifically by dasatinib treatment.
a WT CBL. Our results demonstrate that the proliferation of GDM-1 depends on the absence of WT CBL, consistent with the homozygous nature of mutations in this cell line. GDM-1 also showed hypersensitivity to growth factors, which could be diminished by ectopic expression of WT CBL. We have found that the most effective TKI in GDM-1 was dasatinib, which specifically reduced the phosphorylation levels of KIT, SRC, STAT1 and STAT3 in this highly phosphorylated CBL mutant cell line. Dasatinib also suppressed proliferation of bone marrow cells from an AML patient with homozygous CBL RFD mutation more than that of control bone marrow with WT CBL. Recently, multiple groups found that CBL homozygous mutations are associated with UPD11q in the cases of juvenile myelomonocytic leukemia in which no mutations of the RAS family, PTPN11 or NF1 were found. 13 --16 One of the diagnostic criteria in juvenile myelomonocytic leukemia is GM-CSF hypersensitivity of malignant clone. In analogy to juvenile myelomonocytic leukemia, among various kinds of growth factors tested, proliferation of GDM-1 was highest with GM-CSF treatment; not surprisingly, the GM-CSF receptor is expressed on the cell surface of GDM-1. This hypersensitivity was suppressed by overexpression of WT CBL. Dasatinib specifically reduced phosphorylation of SRC, STAT3 and STAM2, associated with signal transduction downstream of GM-CSF receptor activation. These findings suggest that CBL homozygous mutations might result in hypersensitivity of mutant clone to GM-CSF, as there might be less ubiquitination or degradation of its receptor.
A relatively high frequency of homozygosity of CBL RFD mutations encountered in CMML and CMML-derived AML also implies that the WT allele may protect against malignant evolution. Here, we showed that the WT allele reduces the proliferation and growth factor hypersensitivity in GDM-1 cells. In animal models, WT CBL knockout mice show only mild myeloproliferative potential. 17 However, WT CBL knockout with mutant CBL knock-in developed a more aggressive myeloproliferative disease, which progresses to leukemia and involves hematopoietic progenitors that exhibit augmented FLT3 signaling. 5 Suppressing this pathway through crossbreeding with FLT3 ligand knockout mice prevents leukemia development. 17 These and other findings suggest that FLT3 may be one of the most significant targets of ubiquitination by CBL. 4,11,18 --22 In addition to the GM-CSF receptor, we observed activation of FLT3 in GDM-1 cells; however, enhanced phosphorylation of other RTK and SFK was also detected that was subsequently reduced by TKI. These results suggest that other RTKs, except for FLT3 and SFK, may also be very important for leukemia evolution. In our primary and cell line models, the downstream pathway of receptors of GM-CSF and TPO contribute more than FLT3 signaling. Interestingly, in a CBL and CBLB double knockout mouse model, STAT5 activation was observed after GM-CSF, SCF and TPO stimulation. 23 Of note is that in a recent report, a mutation of CSF1R was described in GDM-1. 24 In this study, GDM-1 showed sensitivity to imatinib but in our report dasatinib showed more suppressive effect than imatinib. In fact, dasatinib showed the most effective inhibition of this CBL mutant cell line among all drugs we screened, and reduced the phosphorylation of specific RTK and non RTK proteins, which may result in an increased proliferative potential in myeloid malignancies with CBL homozygous mutations.
Consequently, it appears that CBL family genes behave as tumor suppressors, because a loss of function results in the reduction of ubiquitination and degradation of activated RTKs. However, mutated CBL also appears to act as an oncogene that induces malignant evolution with a specific phenotype that includes monocytosis and growth factor hypersensitivity. In agreement with this theory, in mutant models CBL seems to act with dual properties: as a tumor suppressor gene and an oncogene, as the phenotype of knock-in models in CBL (À/À) mice showed a more pervasive leukemic phenotype than the simple knockout. 5, 25, 26 In addition to autophosphorylation, activation of various RTKs results in phosphorylation of multiple proteins in their downstream cascades. CBL is critically associated with reducing phosphorylation of RTK or SFK through ubiquitination and degradation. 27 --30 Consequently, our hypothesis was simple: loss of CBL function should result in more phosphorylation. Indeed, we observed tyrosine phosphorylation in 73% of target proteins we examined in GDM-1 without any additional growth factor stimulation or TKI, the highest level of phosphorylation occurring in KIT. In general, mutations of RTK genes, including KIT and FLT3, have been found in hematopoietic malignancies, producing a permanent signal for cell proliferation by activation of the kinase domain in the absence of ligand. However, KIT and FLT3 are not mutated in GDM-1 but are highly phosphorylated, possibly based on inappropriate activation by loss of a negative regulator (CBL RFD). Also, LCK, STAT1 and STAT3 positioned downstream of KIT were phosphorylated in GDM-1, suggesting that this cell line is a strong model for studying the outcomes of KIT overactivation. Similarly, previously reported in vitro models showed that concomitant expression of CBL mutations and KIT induced cytokine-independent proliferation, survival and clonogenic growth. 20, 21 As CBL mutations are related to disease phenotypes with poor prognosis, new therapeutic approaches are required. 4, 6 RTK and SFK inhibitors could suppress growth potential in CBL mutant disease models. Unlike cell lines with WT CBL, GDM-1 showed an increased sensitivity to a RTK and SFK inhibitor, dasatinib. A low concentration of dasatinib was effective in suppressing the proliferation of GDM-1, but at an equivalent dose dasatinib did not suppress cell lines with WT CBL. Inhibitors of mTOR, PI3K or MAPK demonstrated almost equal responses between CBL mutant and WT cell lines. Based on the inhibition spectrum, our results indicate that activating SRC family pathways downstream of RTK are most likely targets involved in the pathogenic process mediated by CBL mutations, whereas downregulation of other signaling cascades including the mTOR, PI3K and MAPK pathways may not be sufficient for the reduction of pro-oncogenic effect of mutant CBL. In an animal model with CBL mutation, one member of the SFK, Fyn, is expressed and binds to CBL and is inhibited by SRC inhibitors. 21 In our experiments, phosphorylation of SRC and LCK were also inhibited specifically by dasatinib therapy. In the future, the same results should be reproduced in vivo, before such therapeutic strategies are to human disorders.
In this paper, we focused our study on the specific mutation of CBL R420Q, because R420 is functionally very important site for ubiquitination and degradation of RTK and most frequently affected site functionally well known for loss of function.
11,21
Although we examined the MOLM-13 cell line with a splice mutation, the spectrum of TKIs' effectiveness was not the same as that in a homozygous CBL R420Q mutation, perhaps because by RT-PCR, both WT and CBL mRNA splice variants were detected in MOLM-13. Functionally, the presence of WT CBL is likely similar to overexpression of the WT protein in a CBL homozygous mutation background (GDM-1). Because WT CBL functions against TK activation and proliferation in GDM-1, it is reasonable that the effect of dasatinib on MOLM-13 was not observed. However, the effect of TKIs on other CBL mutations remains unclear and further investigation is required.
The GDM-1 cell line is known to respond to imatinib and is positive for the CSF1R mutation. 24 Chase et al. 24 showed that CSF1R in GDM-1 is very strongly phosphorylated and that CSF1 neutralization only partially inhibited its proliferation. This result suggests that not only the effect of the driver CSF1R mutation, but also other mechanisms of proliferation, for example, through activation of various TK might be involved as demonstrated by our results. Moreover, we showed that dasatinib almost completely inhibited GDM-1 proliferation with very low concentration. Of course, CSF1R is one of the main targets of dasatinib and the
